| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |